Evidence map›Paper›PMID 41441470›Full record

ArticleNanomaterials (Basel, Switzerland)2025

The Impact of the Reducing Agent on the Cytotoxicity and Selectivity Index of Silver Nanoparticles in Leukemia and Healthy Cells.

Jovani Guadalupe Aguirre-León, Belkis Sulbarán-Rangel, Edsaúl Emilio Pérez-Guerrero, Antonio Topete-Camacho, Trinidad García-Iglesias, Pedro Ernesto Sánchez-Hernández, Moisés Ramos-Solano, Andrea Carolina Machado-Sulbaran

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jovani Guadalupe Aguirre-LeónDoctorado en Farmacología, Departamento de Fisiología, Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara, Sierra Mojada 950, Independencia Oriente, Guadalajara 44340, Jalisco, Mexico.ORCID 0009-0001-1418-1514
Belkis Sulbarán-RangelDepartamento de Estudios del Agua y la Energía, Centro Universitario de Tonalá, Universidad de Guadalajara, Nuevo Periférico Oriente, 555, Ejido San José, Tateposco, Tonalá 45425, Jalisco, Mexico.ORCID 0000-0002-5758-6140
Edsaúl Emilio Pérez-GuerreroInstituto de Investigación en Ciencias Biomédicas, Departamento de Biología Molecular, CUCS, Universidad de Guadalajara, Sierra Mojada 950, Independencia Oriente, Guadalajara 44340, Jalisco, Mexico.ORCID 0000-0002-0007-1824
Antonio Topete-CamachoGrupo de Física de Coloides y Polímeros e Instituto de Materiales (iMATUS), Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain.ORCID 0000-0002-5448-0295
Trinidad García-IglesiasInstituto de Investigación en Cáncer en la Infancia y Adolescencia (INICIA), Departamento de Clínicas de la Reproducción Humana, Crecimiento y Desarrollo Infantil, Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara, Sierra Mojada No. 950, Independencia Oriente, Guadalajara 44340, Jalisco, Mexico.ORCID 0000-0002-8115-7960
Pedro Ernesto Sánchez-HernándezInstituto de Investigación en Cáncer en la Infancia y Adolescencia (INICIA), Departamento de Clínicas de la Reproducción Humana, Crecimiento y Desarrollo Infantil, Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara, Sierra Mojada No. 950, Independencia Oriente, Guadalajara 44340, Jalisco, Mexico.ORCID 0000-0001-5047-8115
Moisés Ramos-SolanoLaboratorio de Investigación en Cáncer e Infecciones, CUCS, Universidad de Guadalajara, Sierra Mojada 950, Independencia Oriente, Guadalajara 44340, Jalisco, Mexico.ORCID 0000-0003-4644-7150
Andrea Carolina Machado-SulbaranInstituto de Investigación en Cáncer en la Infancia y Adolescencia (INICIA), Departamento de Clínicas de la Reproducción Humana, Crecimiento y Desarrollo Infantil, Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara, Sierra Mojada No. 950, Independencia Oriente, Guadalajara 44340, Jalisco, Mexico.ORCID 0000-0001-7879-9316

Funding

Centro Universitario de ciencias de la salud, Universidad de Guadalajara PIN lll, 2022
6 · The paper itself

Abstract

Silver nanoparticles (AgNPs) are widely studied in oncological nanomedicine, although concerns persist regarding their toxicity, elimination, and tissue accumulation. The biological properties of AgNPs depend on the synthesis method and the reducing agent used, which may influence cytotoxicity and cellular metabolism. This study aimed to evaluate the effect of the reducing agent on the cytotoxicity of AgNPs in leukemia (JURKAT) cell lines and peripheral blood mononuclear cells (PBMCs). AgNPs were synthesized via chemical reduction using glucose (GLU) or polyvinylpyrrolidone (PVP) as reducing agents. Nanoparticles were characterized by UV-Vis, FTIR, DLS, zeta potential, and TEM. Cell viability was assessed using trypan blue exclusion, and cytotoxicity was determined using the MTT assay. UV-Vis analysis showed distinct surface plasmon resonance profiles, and FTIR confirmed characteristic functional groups on the nanoparticle surface. DLS and zeta potential values indicated colloidal stability, with PVP-AgNPs presenting a more negative surface charge. TEM revealed greater size heterogeneity in GLU-AgNPs. GLU-AgNPs induced lower cytotoxicity and higher cell viability in JURKAT and PBMCs compared to PVP-AgNPs (

Indexed as

cytotoxicityglucoseleukemiananoparticlespolyvinylpyrrolidonereducing agents

Identifiers

PMID41441470
PMCPMC12736133

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.